MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cognitive Impairment in Parkinson’s disease Patients: a Descriptive Study

R. Nindela, A. Kurniawan, Y. Harun, S. Marisdina, I. Irfannuddin (Palembang, Indonesia)

Meeting: MDS Virtual Congress 2021

Abstract Number: 691

Keywords: Cognitive dysfunction, Parkinson’s

Category: Parkinson's Disease: Cognitive functions

Objective: This study aims to describe the cognitive profile in Parkinson’s disease (PD) patients.

Background: Cognitive impairment is a common non-motor symptom of PD. Cohort studies demonstrated that about 50% of PD patients would develop dementia after ten years, and >80% would develop dementia after 20 years. Cognitive impairment significantly decreases the quality of life of PD patients.

Method: A total of 38 PD patients (based on United Kingdom Parkinson’s Disease Society Bank criteria) at the outpatient clinic of Mohammad Hoesin General Hospital, Palembang, Indonesia, between September 2019 and January 2020 recruited for this study. The severity of the disease examined using the Hoehn and Yahr stage, and the cognitive function was measured using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina). Data were analyzed with SPSS version 22 for windows.

Results: The average age of subjects was 59.9±10.9 years. The majority (55.3%) were diagnosed with PD at the age of ≥60 years. Most subjects (65.8%) were male. A total of 78.9% of subjects finished senior high school or higher. The proportion of subjects in the early stages (stage <3) and the advanced stages of disease (stage ≥3) is approximately the same, 52.6% and 47.4% respectively. Cognitive impairment (MoCA-Ina score <26) was found in 89.5% of subjects; 42.1% of them are from advanced-stage group while the other 47.4% came from early-stage group. Cognitive decline was seen in all domains assessed in MoCA-Ina but visuospatial/executive function (averaged 2.9±1.5 out of a maximum of 5 points) and delayed recall (averaged 1.2±1.6 out of a maximum 4 points) experienced the most significant decrease.

Conclusion: Cognitive impairment is found in the majority of PD patients regardless of the severity of the disease. Most impaired domains are visuospatial/executive function and memory.

References: 1. Chen L, Wang X. Cognitive Function in Early and Advanced Parkinson’s disease. Neuropsychiatry (London) (2018) 8(2): 513-518 2. Goldman JG, et al. Cognitive impairment in Parkinson’s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. Parkinson’s disease (2018) 19: 1-11

To cite this abstract in AMA style:

R. Nindela, A. Kurniawan, Y. Harun, S. Marisdina, I. Irfannuddin. Cognitive Impairment in Parkinson’s disease Patients: a Descriptive Study [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/cognitive-impairment-in-parkinsons-disease-patients-a-descriptive-study/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/cognitive-impairment-in-parkinsons-disease-patients-a-descriptive-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley